1
|
Chavarriaga J, Atenafu EG, Mousa A, Langleben C, Anson-Cartwright L, Jewett M, Hamilton RJ. Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer. Eur Urol Oncol 2024:S2588-9311(24)00032-4. [PMID: 38278693 DOI: 10.1016/j.euo.2024.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 12/07/2023] [Accepted: 01/04/2024] [Indexed: 01/28/2024]
Abstract
BACKGROUND Open retroperitoneal lymph node dissection (O-RPLND) is the accepted standard surgical approach to treat retroperitoneal nodal disease in testis cancer. Increasingly, robotic RPLND (R-RPLND) is being performed due to the potential for lower blood loss, shorter length of stay, and accelerated recovery. OBJECTIVE We have performed a propensity score matching (PSM) analysis comparing the survival and perioperative outcomes of O- and R-RPLND. DESIGN, SETTING, AND PARTICIPANTS Analyzing the data from all patients who underwent primary RPLND at our center between 1990 and 2022, we used PSM to create a 2:1 (O-RPLND:R-RPLND) matched cohort. INTERVENTION Primary O-RPLND versus R-RPLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was time to relapse. The secondary endpoints included operating time, length of stay, estimated blood loss (EBL), and surgical complications. Relapse-free survival rates were calculated using the Kaplan-Meier method, and log-rank tests were used to compare perioperative outcomes of O-RPLND versus R-RPLND. KEY FINDINGS AND LIMITATIONS A total of 178 patients underwent primary RPLND: 137 O-RPLND and 41 R-RPLND. After PSM, 26 patients in the R-RPLND group were matched with 38 in the O-RPLND group. After matching, no significant baseline differences were noted. After a median follow-up of 23.5 mo (interquartile range 4.4-59.2), one (3.8%) relapse was noted in the R-RPLND group versus three (7.8%) in the O-RPLND group; however, this was not significant (hazard ratio 0.65, 95% confidence interval 0.07-6.31, p = 0.7097). No in-field relapses occurred in either cohort. R-RPLND was associated with a shorter length of stay (1 vs 5 d, p < 0.0001) and lower EBL (200 vs 300 ml, p = 0.032), but longer operative time (8.8 vs 4.3 h, p < 0.0001). CONCLUSIONS R-RPLND offers low morbidity and improved perioperative outcomes, while maintaining oncologic efficacy of the open approach. PATIENT SUMMARY To the best of our knowledge, this is the first study to compare open and robotic retroperitoneal lymph node dissection (R-RPLND) using a propensity score-matched system. We encourage the discussion and inclusion of primary R-RPLND into the standard of care algorithm for patients with de novo clinical stage (CS) II and relapsed CS I with CS II equivalent disease.
Collapse
Affiliation(s)
- Julian Chavarriaga
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
| | - Eshetu G Atenafu
- Department of Biostatistics, University Health Network, Toronto, Ontario, Canada
| | - Ahmad Mousa
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | - Carley Langleben
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | - Lynn Anson-Cartwright
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | - Michael Jewett
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | - Robert J Hamilton
- Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
2
|
Richard PO, Violette PD, Bhindi B, Breau RH, Kassouf W, Lavallée LT, Jewett M, Kachura JR, Kapoor A, Noel-Lamy M, Ordon M, Pautler SE, Pouliot F, So AI, Rendon RA, Tanguay S, Collins C, Kandi M, Shayegan B, Weller A, Finelli A, Kokorovic A, Nayak J. Canadian Urological Association guideline: Management of small renal masses - Full-text. Can Urol Assoc J 2022; 16:E61-E75. [PMID: 35133268 PMCID: PMC8932428 DOI: 10.5489/cuaj.7763] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023]
Affiliation(s)
- Patrick O. Richard
- Department of Surgery, Division of Urology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - Philippe D. Violette
- Departments of Health Research Methods Evidence and Impact (HEI) and Surgery, McMaster University, Hamilton, ON, Canada
| | - Bimal Bhindi
- Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada
| | - Rodney H. Breau
- Department of Surgery, Division of Urology, University of Ottawa, Ottawa, ON, Canada
| | - Wassim Kassouf
- Department of Surgery, Division of Urology, McGill University Health Centre, Montreal, QC, Canada
| | - Luke T. Lavallée
- Department of Surgery, Division of Urology, University of Ottawa, Ottawa, ON, Canada
| | - Michael Jewett
- Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, Toronto, ON, Canada
| | - John R. Kachura
- Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada
| | - Anil Kapoor
- McMaster Institute of Urology, St. Joseph Healthcare, Hamilton, ON, Canada
| | - Maxime Noel-Lamy
- Department of Medical Imaging, Division of Interventional Radiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
| | - Michael Ordon
- Department of Surgery, Division of Urology, St. Michael’s Hospital, Toronto, ON, Canada
| | - Stephen E. Pautler
- Department of Surgery, Division of Urology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| | - Frédéric Pouliot
- Department of Surgery, Division of Urology, Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada
| | - Alan I. So
- Division of Urology, British Columbia Cancer Care, Vancouver, BC, Canada
| | - Ricardo A. Rendon
- Department of Surgery, Division of Urology, Capital Health - QEII, Halifax, NS, Canada
| | - Simon Tanguay
- Department of Surgery, Division of Urology, McGill University Health Centre, Montreal, QC, Canada
| | | | - Maryam Kandi
- Departments of Health Research Methods Evidence and Impact (HEI) and Surgery, McMaster University, Hamilton, ON, Canada
| | - Bobby Shayegan
- McMaster Institute of Urology, St. Joseph Healthcare, Hamilton, ON, Canada
| | | | - Antonio Finelli
- Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, Toronto, ON, Canada
| | - Andrea Kokorovic
- Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
| | - Jay Nayak
- Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
3
|
Richard PO, Violette PD, Bhindi B, Breau RH, Kassouf W, Lavallée LT, Jewett M, Kachura JR, Kapoor A, Noel-Lamy M, Ordon M, Paulter SE, Pouliot F, So AI, Rendon RA, Tanguay S, Collins C, Kandi M, Shayegan B, Weller A, Finelli A. Canadian Urological Association guideline: Management of small renal masses – Summary of recommendations. Can Urol Assoc J 2022; 16:24-25. [DOI: 10.5489/cuaj.7760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Cheung D, Frankel J, Tut P, Komisarenko M, Martin L, Jewett M, Finelli A. Treatment on active surveillance of small renal masses: Progression vs. preference. Can Urol Assoc J 2021; 16:97-101. [PMID: 34812722 DOI: 10.5489/cuaj.7451] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Active surveillance (AS) of small renal masses (SRM) is increasingly recognized as a safe option. A recent U.S. study found that half of patients receiving treatment on AS were for preference, but these findings may not be generalizable to other jurisdictions and healthcare models. We aimed to investigate AS failure rates and causes among a contemporary biopsy-evaluated cohort in Canada. METHODS A retrospective review was performed of SRM patients on AS undergoing treatment at our tertiary care center (1999-2018). All patients had undergone renal biopsy and been diagnosed with renal cell carcinoma (RCC). Demographic and clinical parameters surrounding the decision to treat were extracted from chart review. Indications for treatment were dichotomized into clinical (radiographical) progression or preference. Qualitative assessment of clinic notes confirmed treatment indication. Ethics approval was obtained. RESULTS A total of 38 SRM-RCC patients who underwent treatment on AS were identified, of which 29 had been on AS ≥1 year. Most (75.9%) were male, and the mean age beginning AS was 65.9±9.0 years. Most patients had clear-cell RCC with low-grade disease. Seventeen of 29 (58.6%) patients experienced clinical progression after 3.82 (2.57-7.16) years, whereas preference accounted for 12/29 (41.4%) after 2.22 (1.69-3.53) years (time-to-treatment p=0.032). The longest duration on AS was 14.2 years prior to clinical progression. No patients had metastatic progression before treatment. CONCLUSIONS Two-fifths of patients received treatment for preference and at a much higher rate vs. clinical progression. These findings suggest a clinical gap where effective patient counselling, prior to and during AS, may improve adherence.
Collapse
Affiliation(s)
- Douglas Cheung
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Jed Frankel
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Pavinder Tut
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Maria Komisarenko
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Lisa Martin
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Michael Jewett
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Antonio Finelli
- Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada
| |
Collapse
|
5
|
Abu-Ghanem Y, van Thienen JV, Blank C, Aarts MJB, Jewett M, de Jong IJ, Lattouf JB, van Melick HHE, Wood L, Mulders P, Rottey S, Wagstaff J, Zondervan P, Powles T, Neven A, Collette L, Tombal B, Haanen J, Bex A. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. BJU Int 2021; 130:68-75. [PMID: 34706141 DOI: 10.1111/bju.15625] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 10/17/2021] [Accepted: 10/23/2021] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To analyse if exposure to sunitinib in the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial, which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy, is associated with the overall survival (OS) benefit observed in the deferred CN arm. PATIENTS AND METHODS A post hoc analysis of SURTIME trial data. Variables analysed included number of patients receiving sunitinib, time from randomisation to start sunitinib, overall response rate by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, and duration of drug exposure and dose in the intention-to-treat population of the immediate and deferred arm. Descriptive methods and 95% confidence-intervals (CI) were used. RESULTS In the deferred arm, 97.7% (95% CI 89.3-99.6%; n = 48) received sunitinib vs 80% (95% CI 66.9-88.7%, n = 40) in the immediate arm. Following immediate CN, 19.6% progressed 4 weeks after CN and the median time to start sunitinib was 39.5 vs 4.5 days in the deferred arm. At week 16, 46.0% had progressed at metastatic sites in the immediate CN arm vs 32.7% in the deferred arm. Sunitinib dose reductions, escalations and interruptions were not statistically significantly different between arms. Among patients who received sunitinib in the immediate or deferred arm the median total sunitinib treatment duration was 172.5 vs 248 days. Reduction of target lesions was more profound in the deferred arm. CONCLUSIONS In comparison to the deferred CN approach, immediate CN impairs administration, onset, and duration of sunitinib. Starting with systemic therapy leads to early and more profound disease control and identification of progression prior to planned CN, which may have contributed to the observed OS benefit.
Collapse
Affiliation(s)
- Yasmin Abu-Ghanem
- Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK
| | | | | | | | | | - Igle Jan de Jong
- University of Groningen, University Medical Center Groningen, the Netherlands
| | | | | | - Lori Wood
- QEII Health Sciences Center, Halifax, NS, Canada
| | - Peter Mulders
- Radboud University Hospital, Nijmegen, the Netherlands
| | | | - John Wagstaff
- South West Wales Cancer Centre and Swansea University College of Medicine, Swansea, UK
| | | | - Tom Powles
- Barts and Queen Mary University London, London, UK
| | - Anouk Neven
- European Organisation of Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - Laurence Collette
- European Organisation of Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - Bertrand Tombal
- European Organisation of Research and Treatment of Cancer (EORTC), Brussels, Belgium.,Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - John Haanen
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Axel Bex
- Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK.,Netherlands Cancer Institute, Amsterdam, the Netherlands
| |
Collapse
|
6
|
Jimenez-Ferrer I, Bäckström F, Dueñas-Rey A, Jewett M, Boza-Serrano A, Luk KC, Deierborg T, Swanberg M. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease. Brain Behav Immun 2021; 91:369-382. [PMID: 33223048 DOI: 10.1016/j.bbi.2020.10.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 09/24/2020] [Accepted: 10/19/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Abnormal folding, aggregation and spreading of alpha-synuclein (αsyn) is a mechanistic hypothesis for the progressive neuropathology in Parkinson's disease (PD). Spread of αsyn between cells is supported by clinical, neuropathological and experimental evidence. It has been proposed that a pro-inflammatory micro-environment in response to αsyn can promote its aggregation. We have previously shown that allelic differences in the major histocompatibility complex class two transactivator (Mhc2ta) gene, located in the VRA4 locus, alter MHCII expression levels, microglial activation and antigen presentation capacity in rats upon human αsyn over-expression. In addition, Mhc2ta regulated dopaminergic neurodegeneration and the extent of motor impairment. The purpose of this study was to determine whether Mhc2ta regulates αsyn aggregation, propagation and dopaminergic pathology in an αsyn pre-formed fibril (PFF)-seeded in vivo model of PD. METHODS The DA and DA.VRA4 congenic rat strains share background genome but display differential microglial antigen presenting capacity due to different Mhc2ta alleles in the VRA4 locus. PFFs of human αsyn or BSA solution were injected unilaterally to the striatum of DA and DA.VRA4 rats two weeks after ipsilateral administration of recombinant adeno-associated virus (rAAV) vectors carrying human αsyn or GFP to the substantia nigra pars compacta. Behavioural assessment was performed at 2, 5 and 8 weeks while histological evaluation of αsyn pathology, inflammation and neurodegeneration as well as determination of serum cytokine profiles were performed at 8 weeks. RESULTS rAAV-mediated expression of human αsyn in nigral dopaminergic neurons combined with striatal PFF administration induced enhanced αsyn pathology in DA.VRA4 compared to DA rats. Mhc2ta thus significantly regulated the seeding, propagation and toxicity of αsyn in vivo. This was reflected in terms of wider extent and anatomical distribution of αsyn inclusions, ranging from striatum to the forebrain, midbrain, hindbrain and cerebellum in DA.VRA4. Compared to DA rats, DA.VRA4 also displayed enhanced motor impairment and dopaminergic neurodegeneration as well as higher levels of the proinflammatory cytokines IL-2 and TNFα in serum. CONCLUSIONS We conclude that the key regulator of MHCII expression, Mhc2ta, modulates neuroinflammation, αsyn-seeded Lewy-like pathology, dopaminergic neurodegeneration and motor impairment. This makes Mhc2ta and microglial antigen presentation promising therapeutic targets for reducing the progressive neuropathology and clinical manifestations in PD.
Collapse
Affiliation(s)
- Itzia Jimenez-Ferrer
- Translational Neurogenetics Unit, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden
| | - Filip Bäckström
- Translational Neurogenetics Unit, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden
| | - Alfredo Dueñas-Rey
- Translational Neurogenetics Unit, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden
| | - Michael Jewett
- Translational Neurogenetics Unit, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden
| | | | - Kelvin C Luk
- Department of Pathology and Laboratory Medicine, Institute on Aging and Centre for Neurodegenerative Disease Research, Philadelphia, PA, USA
| | - Tomas Deierborg
- Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden
| | - Maria Swanberg
- Translational Neurogenetics Unit, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden.
| |
Collapse
|
7
|
Ribnikar D, Stukalin I, Bedard PL, Hamilton RJ, Jewett M, Warde P, Chung P, Anson-Cartwright L, Templeton AJ, Amir E, Hansen AR, Heng DYC, Lewin J. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. ACTA ACUST UNITED AC 2020; 28:107-114. [PMID: 33622996 PMCID: PMC7816171 DOI: 10.3390/curroncol28010014] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 12/03/2020] [Accepted: 12/15/2020] [Indexed: 01/04/2023]
Abstract
We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatment-derived NLR (dNLR). Predictive accuracy was evaluated using the Cox proportional hazard model adjusted for the international germ cell cancer collaborative group (IGCCCG) risk classification. Discriminatory accuracy was evaluated by determining the area under the receiver operating characteristic curve (AUROC). In total, 569 of 690 patients had available dNLR (IGCCCG: good, 64%; intermediate, 21%; poor, 16%). The 5-year and 10-year overall survivals (OSs) for good, intermediate, and poor risk groups were 96.2%, 92.8%, and 62.7% and 93.9%, 90.3%, and 62.7%, respectively. A dNLR of 2 provided the best discriminatory accuracy with an AUROC of 0.58 (95% CI: 0.52-0.65, p = 0.01) for progression-free survival (PFS), whereas for OS, a dNLR of 3 provided the best discriminatory accuracy with an AUROC of 0.62 (95% CI: 0.53-0.70, p < 0.01). A dNLR > 2 was associated with a hazard ratio (HR) of 1.99 (95% CI: 1.27-3.12, p < 0.01) for PFS, which lost its effect after adjustment for IGCCCG (HR: 1.44, 95% CI: 0.90-2.30, p = 0.13). For OS, a dNLR >3 was associated with an HR of 3.00 (95% CI: 1.79-5.01, p < 0.01), but lost its effect after adjustment for IGCCCG. Systemic inflammation plays a role in metastatic GCT, but its prognostic utility beyond established algorithms is limited. The general prognostic value of NLR can be seen across a number of tumors, although the consistency and magnitude of the effect differ according to cancer type, disease stage, and treatment received. We identified that an elevated NLR was associated with an adverse PFS and OS, but not independent of the IGCCCG risk classification. dNLRs >2 and >3 were associated with an adverse PFS and OS, respectively, in patients with metastatic GCT receiving first-line chemotherapy, but not independent of the IGCCCG risk classification.
Collapse
Affiliation(s)
- Domen Ribnikar
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (D.R.); (P.L.B.); (E.A.); (A.R.H.)
| | - Igor Stukalin
- Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada; (I.S.); (D.Y.C.H.)
| | - Philippe L. Bedard
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (D.R.); (P.L.B.); (E.A.); (A.R.H.)
| | - Robert J. Hamilton
- Princess Margaret Cancer Centre, Department of Surgery, University Health Network, 610 University Ave 3-130, Toronto, ON M5G 2C1, Canada; (R.J.H.); (M.J.)
| | - Michael Jewett
- Princess Margaret Cancer Centre, Department of Surgery, University Health Network, 610 University Ave 3-130, Toronto, ON M5G 2C1, Canada; (R.J.H.); (M.J.)
| | - Padraig Warde
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (P.W.); (P.C.); (L.A.-C.)
| | - Peter Chung
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (P.W.); (P.C.); (L.A.-C.)
| | - Lynn Anson-Cartwright
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (P.W.); (P.C.); (L.A.-C.)
| | - Arnoud J. Templeton
- Department of Oncology, St. Claraspital Basel, and Faculty of Medicine, University of Basel, CH-4058 Basel, Switzerland;
| | - Eitan Amir
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (D.R.); (P.L.B.); (E.A.); (A.R.H.)
| | - Aaron R. Hansen
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (D.R.); (P.L.B.); (E.A.); (A.R.H.)
| | - Daniel Y. C. Heng
- Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada; (I.S.); (D.Y.C.H.)
| | - Jeremy Lewin
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada; (D.R.); (P.L.B.); (E.A.); (A.R.H.)
- Correspondence: ; Tel.: +61-3-8559-5000
| |
Collapse
|
8
|
|
9
|
Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5:164-170. [PMID: 30543350 DOI: 10.1001/jamaoncol.2018.5543] [Citation(s) in RCA: 286] [Impact Index Per Article: 57.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. Design, Setting, and Participants This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. Interventions Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. Main Outcomes and Measures Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. Results The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (P = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95; P = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). Conclusions and Relevance Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. Trial Registration ClinicalTrials.gov identifier: NCT01099423.
Collapse
Affiliation(s)
- Axel Bex
- The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Peter Mulders
- Department of Urology, Radboud University Hospital, Nijmegen, the Netherlands
| | - Michael Jewett
- Department of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - John Wagstaff
- Department of Oncology, Cardiff Hospital, Wales, United Kingdom
| | | | | | | | | | - Lori Wood
- Division of Medical Oncology, QEII Health Sciences Center, Halifax, Nova Scotia, Canada
| | | | - Maureen J Aarts
- Department of Oncology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - J B Lattouf
- Department of Surgery-Urology, University of Montreal Hospital Center, Quebec, Ontario, Canada
| | - Thomas Powles
- Department of Oncology, The Royal Free Hospital and Queen Mary University, London, United Kingdom
| | - Igle Jan de Jong Md PhD
- Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Sylvie Rottey
- Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
| | - Bertrand Tombal
- Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Sandrine Marreaud
- Department of Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - Sandra Collette
- Department of Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.,Currently with Bristol-Myers Squibb, Brussels, Belgium
| | - Laurence Collette
- Department of Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - John Haanen
- The Netherlands Cancer Institute, Amsterdam, the Netherlands
| |
Collapse
|
10
|
Giles R, Maskens D, Bick R, Martinez R, Packer M, Bex A, Heng D, Larkin J, Maclennan S, Jewett M, Jonasch E. Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Rumaihi KA, Boorjian SA, Jewett M. Evolving Changes in the Delivery of Health Services: A Place for Urological Homecare? Eur Urol 2019; 75:543-545. [DOI: 10.1016/j.eururo.2018.10.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 10/13/2018] [Indexed: 11/30/2022]
|
12
|
Affiliation(s)
- Anne d'Aquino
- Interdisciplinary Biological SciencesNorthwestern UniversityEvanstonIL
- Chemistry of Life Processes InstituteNorthwestern UniversityEvanstonIL
| | - Tasfia Azim
- Chemistry of Life Processes InstituteNorthwestern UniversityEvanstonIL
- Chemical and Biological EngineeringNorthwestern UniversityEvanstonIL
| | - Nikolay Aleksashin
- Center for Pharmaceutical BiotechnologyUniversity of Illinois at ChicagoChicagoIL
| | - Adam Hockenberry
- Interdisciplinary Biological SciencesNorthwestern UniversityEvanstonIL
- Chemistry of Life Processes InstituteNorthwestern UniversityEvanstonIL
| | - Kim Hoang
- Biological Science DepartmentJohnson and Wales UniversityProvidenceRI
| | - Alysse DeFoe
- Chemical and Biological EngineeringNorthwestern UniversityEvanstonIL
| | - Michael Jewett
- Chemistry of Life Processes InstituteNorthwestern UniversityEvanstonIL
- Chemical and Biological EngineeringNorthwestern UniversityEvanstonIL
| |
Collapse
|
13
|
Sanmamed N, Glicksman R, Thoms J, Zlotta A, Finelli A, Van Der Kwast T, Sweet J, Jewett M, Klotz L, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A. A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
60 Background: Pre-operative radiotherapy (PreORT) improves local control in various cancer types, and has become an established oncologic treatment strategy. During 2001-2004, we conducted a phase I pilot study assessing the role of short-course PreORT for men with unfavourable intermediate- and high-risk localized prostate cancer (PCa). We present long-term follow-up toxicity and oncologic outcomes. Methods: Eligible patients had histologically proven PCa, cT1-T2N0M0, PSA > 15-35 ng/ml with any Gleason score, or PSA 10-15 ng/ml with Gleason score ≥7. Patients received 25 Gy in five consecutive daily fractions to the prostate, followed by radical prostatectomy (RadP) within 14 days after RT completion. Primary outcomes were intra-operative morbidity, and late genitourinary (GU) and gastrointestinal (GI) toxicities. Acute toxicity was assessed during radiotherapy treatment on daily basis using RTOG grade scoring scale. Patients were assessed post-RadP clinically and with PSA at 1 and 6 months, and every 6 months. Intra- and Post-RadP toxicity was documented prospectively and scored as per Common Terminology Criteria for Adverse Events v4.0. Biochemical failure (BF) was determined based on two consecutive post-RadP PSA > 0.2 ng/ml. Results: Fifteen patients were enrolled; 14 patients completed PreORT followed by RadP, which also included bilateral lymph node dissections in 13 cases. Median follow-up was 12.2 years (range 6.7-16.3 years). Late GU toxicity was common, with 2 patients (14.3%) experiencing G2 toxicity, and 6 patients (42.8%) G3 toxicity. There were no G4-5 late GU toxicity. Late GI toxicity was infrequent, with only 1 patient (7.1%) experiencing transient G2 proctitis. At last follow-up, 8 (57.1%) and 6 (42.8%) patients experienced BF and metastatic disease recurrence, respectively. Conclusions: The use of PreORT in men with high-risk PCa is associated with unexpected high-rates of late GU toxicity. Future studies examining the role of RT pre-RadP must cautiously select RT technique and dose schedule. Importantly, long-term follow-up data is essential to fully determine the therapeutic index of PreORT in the management of localized PCa. Clinical trial information: NCT00252447.
Collapse
Affiliation(s)
| | | | - John Thoms
- Memorial University of Newfoundland, St Johns, NF, Canada
| | - Alexandre Zlotta
- Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | | | | | - Joan Sweet
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | | | - Laurence Klotz
- Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - Tara Rosewall
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Neil Eric Fleshner
- Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | | | - Padraig Warde
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Alejandro Berlin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
14
|
Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. Clin Drug Investig 2019; 38:1155-1165. [PMID: 30267257 DOI: 10.1007/s40261-018-0705-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND OBJECTIVE The development of new targeted therapies in kidney cancer has shaped disease management in the metastatic phase. Our study aims to conduct a cost-utility analysis of sunitinib versus pazopanib in first-line setting in Canada for metastatic renal cell carcinoma (mRCC) patients using real-world data. METHODS A Markov model with Monte-Carlo microsimulations was developed to estimate the clinical and economic outcomes of patients treated in first-line with sunitinib versus pazopanib. Transition probabilities were estimated using observational data from a Canadian database where real-life clinical practice was captured. The costs of therapies, disease progression, and management of adverse events were included in the model in Canadian dollars ($Can). Utility and disutility values were included for each health state. Incremental cost-utility ratio (ICUR) and incremental cost-effectiveness ratios (ICER) were calculated for a time horizon of 5 years, from the Canadian Healthcare System perspective. RESULTS The cost difference was $36,303 and the difference in quality-adjusted life year (QALY) was 0.54 in favour of sunitinib with an ICUR of $67,227/QALY for sunitinib versus pazopanib. The major cost component (56%) is related to best supportive care (BSC) where patients tend to stay for a longer period of time compared to other states. The difference in life years gained (LYG) between sunitinib and pazopanib was 1.21 LYG (33.51 vs 19.03 months) and the ICER was $30,002/LYG. Sensitivity analysis demonstrated the robustness of the model with a high probability of sunitinib being a cost-effective option when compared to pazopanib. CONCLUSION When using real-world evidence, sunitinib is found to be a cost-effective treatment compared to pazopanib in mRCC patients in Canada.
Collapse
Affiliation(s)
- Sara Nazha
- McGill University Health Center, Montreal, QC, Canada
| | - Simon Tanguay
- McGill University Health Center, Montreal, QC, Canada
| | | | | | | | - Lori Wood
- Dalhousie University and Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada
| | | | - Daniel Heng
- Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
| | - Denis Soulières
- Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada
| | | | - Naveen Basappa
- Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - Eric Lévesque
- Centre Hospitalier Universitaire de Québec, Université de Laval, Quebec, QC, Canada
| | - Alice Dragomir
- Health Economics and Outcomes Research, Research Institute of the McGill University Health Center, Surgery/Urology, McGill University, 5252 Maisonneuve West, Montreal, QC, H4A 3S5, Canada.
| |
Collapse
|
15
|
Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A. A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. Int J Radiat Oncol Biol Phys 2019; 104:61-66. [PMID: 30625410 DOI: 10.1016/j.ijrobp.2018.12.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 12/22/2018] [Accepted: 12/30/2018] [Indexed: 12/30/2022]
Abstract
PURPOSE Neoadjuvant radiation therapy (RT) improves disease control in various cancers and has become an established oncologic treatment strategy. During 2001 to 2004, we conducted a phase 1 pilot study assessing the role of short-course preoperative RT (PreORT) for men with unfavorable intermediate- and high-risk localized prostate cancer. Herein, we present long-term follow-up toxicity and oncologic outcomes. METHODS AND MATERIALS Eligible patients had histologically proven prostate cancer, cT1-T2N0M0 disease, prostate-specific antigen >15 to 35 ng/mL regardless of Gleason score, or prostate-specific antigen 10 to 15 ng/mL with Gleason score ≥7. Patients received 25 Gy in 5 consecutive daily fractions (5 Gy per fraction) to the prostate only, followed by radical prostatectomy within 14 days after RT completion. Primary outcomes were intraoperative morbidity and late genitourinary (GU) and gastrointestinal toxicities. RESULTS In total, 15 patients were enrolled; 14 patients completed PreORT followed by radical prostatectomy, which also included bilateral lymph node dissections in 13 cases. Median follow-up was 12.2 years (range, 6.7-16.3). Late GU toxicity was common, with 2 patients (13.3%) experiencing G2 toxicity and 6 patients (40%) G3 toxicity. There were no patients with G4 to G5 late GU toxicity. Late gastrointestinal toxicity was infrequent, with only 1 patient (6.7%) experiencing transient G2 proctitis. At last follow-up, 8 (53.3%) and 6 (40%) patients experienced biochemical and metastatic disease recurrence, respectively. CONCLUSIONS The use of PreORT in men with high-risk prostate cancer is associated with unexpected high rates of late GU toxicity. Future studies examining the role of RT preradical prostatectomy must cautiously select RT technique and dose schedule. Importantly, long-term follow-up data are essential to fully determine the therapeutic index of PreORT in the management of localized disease.
Collapse
Affiliation(s)
- Rachel Glicksman
- Department of Radiation Oncology, University of Toronto, Toronto, Canada.
| | - Noelia Sanmamed
- Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - John Thoms
- Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| | - Alexandre R Zlotta
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Antonio Finelli
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Theodorus van der Kwast
- Department of Pathology, Toronto General Hospital, University Health Network, Toronto, Canada
| | - Joan Sweet
- Department of Pathology, Toronto General Hospital, University Health Network, Toronto, Canada
| | - Michael Jewett
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Laurence H Klotz
- Department of Surgery (Urology), Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Tara Rosewall
- Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Neil E Fleshner
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Robert G Bristow
- Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom
| | - Padraig Warde
- Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Alejandro Berlin
- Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Techna Institute, University Health Network, Toronto, Canada.
| |
Collapse
|
16
|
Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallée LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, Rendon R, Fergusson DA. Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. BMJ Open 2019; 9:e025662. [PMID: 30610026 PMCID: PMC6326302 DOI: 10.1136/bmjopen-2018-025662] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
INTRODUCTION Partial nephrectomy is a standard of care for non-metastatic renal tumours when technically feasible. Despite the increased use of partial nephrectomy, intraoperative techniques that lead to optimal renal function after surgery have not been rigorously studied. Clamping of the renal hilum to prevent bleeding during resection causes temporary renal ischaemia. The internal temperature of the kidney may be lowered after the renal hilum is clamped (renal hypothermia) in an attempt to mitigate the effects of ischaemia. Our objective is to determine if renal hypothermia during open partial nephrectomy results in improved postoperative renal function at 12 months following surgery as compared with warm ischaemia (no renal hypothermia). METHODS AND ANALYSES This is a multicentre, randomised, single-blinded controlled trial comparing renal hypothermia versus no hypothermia during open partial nephrectomy. Due to the nature of the intervention, complete blinding of the surgical team is not possible; however, surgeons will be blinded until the time of hilar clamping. Glomerular filtration will be based on plasma clearance of a radionucleotide, and differential renal function will be based on renal scintigraphy. The primary outcome is overall renal function at 12 months measured by the glomerular filtration rate (GFR). Secondary outcomes include change in GFR, GFR of the affected kidney, change in GFR of the affected kidney, serum creatinine, haemoglobin, spot urine albumin to creatinine ratio, quality of life and postoperative complications. Data will be collected at baseline, immediately postoperatively and at 3, 6, 9 and 12 months postoperatively. ETHICS AND DISSEMINATION Ethics approval was obtained for all participating study sites. Results of the trial will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER NCT01529658; Pre-results.
Collapse
Affiliation(s)
- Rodney H Breau
- Division of Urology, Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Ilias Cagiannos
- Division of Urology, Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Greg Knoll
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Christopher Morash
- Division of Urology, Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Sonya Cnossen
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Luke T Lavallée
- Division of Urology, Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Ranjeeta Mallick
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Antonio Finelli
- Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | - Michael Jewett
- Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada
| | | | - Jonathan Cook
- Oxford Clinical Trial Research Unit, University of Oxford, Oxford, UK
| | - Louise LeBel
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Anil Kapoor
- Division of Urology, McMaster University, Hamilton, Ontario, Canada
| | - Frederic Pouliot
- Division of Urology, Université Laval, Quebec City, Quebec, Canada
| | - Jonathan Izawa
- Division of Urology, Department of Surgery, Western University, London, Ontario, Canada
| | - Ricardo Rendon
- Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Dean A Fergusson
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|
17
|
Matthew A, Lutzky-Cohen N, Jamnicky L, Currie K, Gentile A, Mina DS, Fleshner N, Finelli A, Hamilton R, Kulkarni G, Jewett M, Zlotta A, Trachtenberg J, Yang Z, Elterman D. The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy. ACTA ACUST UNITED AC 2018; 25:393-402. [PMID: 30607114 DOI: 10.3747/co.25.4111] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose The most prevalent intervention for localized prostate cancer (pca) is radical prostatectomy (rp), which has a 10-year relative survival rate of more than 90%. The improved survival rate has led to a focus on reducing the burden of treatment-related morbidity and improving the patient and partner survivorship experience. Post-rp sexual dysfunction (sdf) has received significant attention, given its substantial effect on patient and partner health-related quality of life. Accordingly, there is a need for sdf treatment to be a fundamental component of pca survivorship programming. Methods Most research about the treatment of post-rp sdf involves biomedical interventions for erectile dysfunction (ed). Although findings support the effectiveness of pro-erectile agents and devices, most patients discontinue use of such aids within 1 year after their rp. Because side effects of pro-erectile treatment have proved to be inadequate in explaining the gap between efficacy and ongoing use, current research focuses on a biopsychosocial perspective of ed. Unfortunately, there is a dearth of literature describing the components of a biopsychosocial program designed for the post-rp population and their partners. Results In this paper, we detail the development of the Prostate Cancer Rehabilitation Clinic (pcrc), which emphasizes multidisciplinary intervention teams, active participation by the partner, and a broad-spectrum medical, psychological, and interpersonal approach. Conclusions The goal of the pcrc is to help patients and their partners achieve optimal sexual health and couple intimacy after rp, and to help design cost-effective and beneficial rehabilitation programs.
Collapse
Affiliation(s)
- A Matthew
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - N Lutzky-Cohen
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - L Jamnicky
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - K Currie
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - A Gentile
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - D Santa Mina
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - N Fleshner
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - A Finelli
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - R Hamilton
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - G Kulkarni
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - M Jewett
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - A Zlotta
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - J Trachtenberg
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - Z Yang
- Department of Surgical Oncology, University Health Network, Toronto, ON
| | - D Elterman
- Department of Surgical Oncology, University Health Network, Toronto, ON
| |
Collapse
|
18
|
Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason G, Heng D, Soulières D, Reaume N, Basappa N, Lévesque E, Dragomir A. Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. ACTA ACUST UNITED AC 2018; 25:e576-e584. [PMID: 30607126 DOI: 10.3747/co.25.4103] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction Outside of randomized controlled clinical trials, the understanding of the effectiveness and costs associated with targeted therapies for metastatic renal cell carcinoma (mrcc) is limited in Canada. The purpose of the present study was to use real-world prospective data to assess the effectiveness and cost of targeted therapies for patients with mrcc. Methods The Canadian Kidney Cancer Information System, a pan-Canadian database, was used to identify prospectively collected data relating to patients with mrcc. First- and subsequent-line time to treatment termination (ttt) was determined from therapy initiation time (sunitinib or pazopanib) to discontinuation of therapy. Kaplan-Meier survival curves were used to estimate the unadjusted and adjusted overall survival (os) by treatment. Unit treatment cost was used to estimate the cost by line of treatment and the total cost of therapy for the management of patients with mrcc. Results The study included 475 patients receiving sunitinib or pazopanib in the first-line setting. Patients were treated mostly with sunitinib (81%); 19% of patients were treated with pazopanib. The median ttt in the first line was 7.7 months for patients receiving sunitinib and 4.6 months for those receiving pazopanib (p < 0.001). The adjusted os was 32 months with sunitinib and 21 months with pazopanib (hazard ratio: 1.61; p < 0.01). The total median cost of first- and second-line treatments was $56,476 (interquartile range: $23,738-$130,447) for patients in the sunitinib group and $46,251 (interquartile range: $28,167-$91,394) for those in the pazopanib group. Conclusions For the two therapies, os differed significantly, with a higher median os being observed in the sunitinib group. The cost of treatment was higher in the sunitinib group, which is to be expected with longer survival.
Collapse
Affiliation(s)
- S Nazha
- McGill University Health Centre, Montreal, QC
| | - S Tanguay
- McGill University Health Centre, Montreal, QC
| | - A Kapoor
- McMaster University, Hamilton, ON
| | - M Jewett
- Princess Margaret Cancer Centre, Toronto, ON
| | | | - L Wood
- Dalhousie University and qeii Health Sciences Centre, Halifax, NS
| | - G Bjarnason
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON
| | - D Heng
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB
| | - D Soulières
- Centre hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC
| | - N Reaume
- University of Ottawa, Ottawa, ON
| | - N Basappa
- Cross Cancer Institute, University of Alberta, Edmonton, AB
| | - E Lévesque
- Centre hospitalier universitaire de Québec, University of Laval, Quebec City, QC
| | - A Dragomir
- McGill University Health Centre, Montreal, QC
| |
Collapse
|
19
|
Jewett M, Dickson E, Brolin K, Negrini M, Jimenez-Ferrer I, Swanberg M. Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson's Disease. Front Neurol 2018; 9:222. [PMID: 29681884 PMCID: PMC5897443 DOI: 10.3389/fneur.2018.00222] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Accepted: 03/21/2018] [Indexed: 12/21/2022] Open
Abstract
Parkinson’s disease (PD) is a common, progressive neurodegenerative disease, which typically presents itself with a range of motor symptoms, like resting tremor, bradykinesia, and rigidity, but also non-motor symptoms such as fatigue, constipation, and sleep disturbance. Neuropathologically, PD is characterized by loss of dopaminergic cells in the substantia nigra pars compacta (SNpc) and Lewy bodies, neuronal inclusions containing α-synuclein (α-syn). Mutations and copy number variations of SNCA, the gene encoding α-syn, are linked to familial PD and common SNCA gene variants are associated to idiopathic PD. Large-scale genome-wide association studies have identified risk variants across another 40 loci associated to idiopathic PD. These risk variants do not, however, explain all the genetic contribution to idiopathic PD. The rat Vra1 locus has been linked to neuroprotection after nerve- and brain injury in rats. Vra1 includes the glutathione S-transferase alpha 4 (Gsta4) gene, which encodes a protein involved in clearing lipid peroxidation by-products. The DA.VRA1 congenic rat strain, carrying PVG alleles in Vra1 on a DA strain background, was recently reported to express higher levels of Gsta4 transcripts and to display partial neuroprotection of SNpc dopaminergic neurons in a 6-hydroxydopamine (6-OHDA) induced model for PD. Since α-syn expression increases the risk for PD in a dose-dependent manner, we assessed the neuroprotective effects of Vra1 in an α-syn-induced PD model. Human wild-type α-syn was overexpressed by unilateral injections of the rAAV6-α-syn vector in the SNpc of DA and DA.VRA1 congenic rats. Gsta4 gene expression levels were significantly higher in the striatum and midbrain of DA.VRA1 compared to DA rats at 3 weeks post surgery, in both the ipsilateral and contralateral sides. At 8 weeks post surgery, DA.VRA1 rats suffered significantly lower fiber loss in the striatum and lower loss of dopaminergic neurons in the SNpc compared to DA. Immunofluorescent stainings showed co-expression of Gsta4 with Gfap at 8 weeks suggesting that astrocytic expression of Gsta4 underlies Vra1-mediated neuroprotection to α-syn induced pathology. This is the second PD model in which Vra1 is linked to protection of the nigrostriatal pathway, solidifying Gsta4 as a potential therapeutic target in PD.
Collapse
Affiliation(s)
- Michael Jewett
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| | - Elna Dickson
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| | - Kajsa Brolin
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| | - Matilde Negrini
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| | - Itzia Jimenez-Ferrer
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| | - Maria Swanberg
- Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
| |
Collapse
|
20
|
Leão R, van Agthoven T, Fadaak K, Castelo-Branco P, Jewett M, Sweet J, E. Ahmad A, Anson-Cartwright L, Chung P, Hansen A, Warde P, O’Malley M, L. Bedard P, H.J. Looijenga L, J Hamilton R. MP37-08 SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
21
|
Goldenberg M, Elfassy M, Jewett M, Lorenzo A, Roberts M, Domes T, Mahdi M, Grober E. PD58-05 REAL-TIME INTRAOPERATIVE SURGICAL COMPETENCY (RISC) ASSESSMENTS: DEVELOPMENT AND VALIDATION OF A PROCEDURE-SPECIFIC EVALUATION TOOL FOR TRANSURETHRAL RESECTION OF BLADDER TUMORS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
22
|
Goldberg H, Chandrasekar T, Klaassen Z, Breau R, Malick R, Maloni R, Fleshner N, Kulkarni G, Hamilton R, Zlotta A, Rendon R, Tanguay S, Kawakami J, Lavallee L, Pouliot F, Jewett M, Finelli A. MP48-15 DOES PARTIAL NEPHRECTOMY FOR BIOPSY PROVEN FUHRMAN GRADE 3/4 RENAL CELL CARCINOMA CONFER WORSE OUTCOMES COMPARED TO RADICAL NEPHRECTOMY? RESULTS FROM A CANADIAN MUTLICENTER COHORT. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Patel P, Nayak JG, Liu Z, Saarela O, Jewett M, Rendon R, Kapoor A, Black P, Tanguay S, Kawakami J, Moore R, Breau RH, Morash C, Pouliot F, Drachenberg DE. A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. J Endourol 2018; 31:645-650. [PMID: 28381117 DOI: 10.1089/end.2016.0787] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
INTRODUCTION To compare outcomes following laparoscopic renal surgery (LRS) and open renal surgery (ORS) in the treatment of pathologic T3a (pT3a) renal cell carcinoma (RCC) using a propensity matched analysis. MATERIALS AND METHODS The Canadian Kidney Cancer Information System is a prospectively maintained database for patients diagnosed with RCC from 15 Canadian institutions. Patients treated for nonmetastatic pT3a RCC between 2008 and 2015 were included. Propensity score matching for age, gender, tumor size, grade, histology, and surgical approach was performed to compare laparoscopic radical and partial nephrectomy (LRN or LPN) with open radical or partial nephrectomy (ORN or OPN). The primary endpoint was recurrence-free survival (RFS). RESULTS Two hundred twenty-six (45%) patients underwent LRS (88% LRN and 12% LPN), and 275 (55%) underwent ORS (75% ORN and 25% OPN). After a median follow-up of 21.1 months, 155 (72 LRS and 83 ORS) patients experienced recurrence. The 3-year RFS was 63% and 50% for the LRS and ORS groups, respectively, p = 0.36. On subgroup analysis, there was no significant difference in RFS among patients who underwent radical nephrectomy (3-year RFS 61% in LRN compared with 46% in ORN group, p = 0.32) or partial nephrectomy (77% in LPN compared with 79% in OPN group, p = 0.82). CONCLUSIONS This study is the largest matched analysis comparing LRS and ORS for pT3a RCC. In matched patients, LRS showed no difference in oncologic outcomes compared with ORS and should be considered when technically feasible.
Collapse
Affiliation(s)
- Premal Patel
- 1 Section of Urology, University of Manitoba , Winnipeg, Canada
| | - Jasmir G Nayak
- 1 Section of Urology, University of Manitoba , Winnipeg, Canada
| | | | - Olli Saarela
- 3 Dalla Lana School of Public Health, University of Toronto , Toronto, Canada
| | - Michael Jewett
- 4 Division of Urology, University of Toronto , Toronto, Canada
| | - Ricardo Rendon
- 5 Department of Urology, Dalhousie University , Halifax, Canada
| | - Anil Kapoor
- 6 Division of Urology, McMaster University , Hamilton, Canada
| | - Peter Black
- 7 Department of Urologic Sciences, University of British Columbia , Vancouver, Canada
| | - Simon Tanguay
- 8 Division of Urology, McGill University , Montreal, Canada
| | - Jun Kawakami
- 9 Southern Alberta Institute of Urology, University of Calgary , Calgary, Canada
| | - Ronald Moore
- 10 Division of Urology, University of Alberta , Edmonton, Canada
| | - Rodney H Breau
- 11 Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa , Ottawa, Canada
| | - Chris Morash
- 11 Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa , Ottawa, Canada
| | - Frédéric Pouliot
- 12 Centre Hospitalier Universitaire de Québec , Quebec City, Canada
| | | |
Collapse
|
24
|
Bex A, Mulders P, Jewett M, Wagstaff J, Van Velthoven R, Laguna P, Wood L, Van Melick H, Soetekouw P, Lattouf J, Powles T, De Jong I, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/s1569-9056(18)30856-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
25
|
Harshman L, Drake C, Haas N, Manola J, Puligandla M, Signoretti S, Cella D, Gupta R, Bhatt R, Van Allen E, Lara P, Choueiri T, Kapoor A, Heng D, Shuch B, Jewett M, George D, Michaelson D, Carducci M, McDermott D, Allaf M. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. Kidney Cancer 2017; 1:31-40. [PMID: 30334002 PMCID: PMC6179104 DOI: 10.3233/kca-170010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is generally tolerable. Mouse solid tumor models have revealed a benefit with a short course of neoadjuvant PD-1 blockade compared to adjuvant therapy. Two ongoing phase 2 studies of perioperative nivolumab in RCC patients have shown preliminary feasibility and safety with no surgical delays or complications. The recently opened PROSPER RCC trial (A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy; EA8143) will examine if the addition of perioperative nivolumab to radical or partial nephrectomy can improve clinical outcomes in patients with high risk localized and locally advanced RCC. With the goal of increasing cure and recurrence-free survival (RFS) rates in non-metastatic RCC, we are executing a three-pronged, multidisciplinary approach of presurgical priming with nivolumab followed by resection and adjuvant PD-1 blockade. We plan to enroll 766 patients with clinical stage ≥T2 or node positive M0 RCC of any histology in this global, randomized, unblinded, phase 3 National Clinical Trials Network study. The investigational arm will receive two doses of nivolumab 240 mg IV prior to surgery followed by adjuvant nivolumab for 9 months. The control arm will undergo the current standard of care: surgical resection followed by observation. Patients are stratified by clinical T stage, node positivity, and histology. The trial is powered to detect a 14.4% absolute benefit in the primary endpoint of RFS from the ASSURE historical control of 55.8% to 70.2% at 5 years (HR = 0.70). The study is also powered to detect a significant overall survival benefit (HR 0.67). Key safety, feasibility, and quality of life endpoints are incorporated. PROSPER RCC exemplifies team science with a host of planned correlative work to investigate the impact of the baseline immune milieu and changes after neoadjuvant priming on clinical outcomes.
Collapse
Affiliation(s)
- L.C. Harshman
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
| | - C.G. Drake
- Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - N.B. Haas
- Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - J. Manola
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - M. Puligandla
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - S. Signoretti
- Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA
| | - D. Cella
- Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - R.T. Gupta
- Departments of Radiology and Surgery and The Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - R. Bhatt
- Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - E. Van Allen
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
| | - P. Lara
- University of California Davis School of Medicine, Sacramento, CA, USA
| | - T.K. Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
| | - A. Kapoor
- Division of Urology, McMaster University, Hamilton, ON, Canada
| | - D.Y.C. Heng
- Tom Baker Cancer Center, Calgary, AB, Canada
| | - B. Shuch
- Division of Urology, Yale Cancer Institute, New Haven, CT, USA
| | - M. Jewett
- Departments of Surgery(Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada
| | - D. George
- Duke University Departments of Medicine, Surgery, and Pharmacology and Cancer Biology, Division of Medical Oncology, The Duke Cancer Institute, Durham, NC, USA
| | - D. Michaelson
- Genitourinary Cancer Center, Massachusetts General Hospital, Boston, MA, USA
| | - M.A. Carducci
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
| | - D. McDermott
- Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - M. Allaf
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
| |
Collapse
|
26
|
Jewett M, Jimenez-Ferrer I, Swanberg M. Astrocytic Expression of GSTA4 Is Associated to Dopaminergic Neuroprotection in a Rat 6-OHDA Model of Parkinson's Disease. Brain Sci 2017; 7:brainsci7070073. [PMID: 28672859 PMCID: PMC5532586 DOI: 10.3390/brainsci7070073] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 06/20/2017] [Accepted: 06/22/2017] [Indexed: 12/22/2022] Open
Abstract
Idiopathic Parkinson’s disease (PD) is a complex disease caused by multiple, mainly unknown, genetic and environmental factors. The Ventral root avulsion 1 (Vra1) locus on rat chromosome 8 includes the Glutathione S-transferase alpha 4 (Gsta4) gene and has been identified in crosses between Dark Agouti (DA) and Piebald Virol Glaxo (PVG) rat strains as being associated to neurodegeneration after nerve and brain injury. The Gsta4 protein clears lipid peroxidation by-products, a process suggested to being implicated in PD. We therefore investigated whether PVG alleles in Vra1 are neuroprotective in a toxin-induced model of PD and if this effect is coupled to Gsta4. We performed unilateral 6-hydroxydopamine (6-OHDA) partial lesions in the striatum and compared the extent of neurodegeration in parental (DA) and congenic (DA.VRA1) rats. At 8 weeks after 6-OHDA lesion, DA.VRA1 rats displayed a higher density of remaining dopaminergic fibers in the dorsolateral striatum compared to DA rats (44% vs. 23%, p < 0.01), indicating that Vra1 alleles derived from the PVG strain protect dopaminergic neurons from 6-OHDA toxicity. Gsta4 gene expression levels in the striatum and midbrain were higher in DA.VRA1 congenic rats compared to DA at 2 days post-lesion (p < 0.05). The GSTA4 protein co-localized with astrocytic marker GFAP, but not with neuronal marker NeuN or microglial marker IBA1, suggesting astrocyte-specific expression. This is the first report on Vra1 protective effects on dopaminergic neurodegeneration and encourages further studies on Gsta4 in relation to PD susceptibility.
Collapse
Affiliation(s)
- Michael Jewett
- Translational Neurogenetics Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, BMC A10, Sölvegatan 17, 221 84 Lund, Sweden.
| | - Itzia Jimenez-Ferrer
- Translational Neurogenetics Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, BMC A10, Sölvegatan 17, 221 84 Lund, Sweden.
| | - Maria Swanberg
- Translational Neurogenetics Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, BMC A10, Sölvegatan 17, 221 84 Lund, Sweden.
| |
Collapse
|
27
|
Fransen van de Putte E, van der Kwast T, Bertz S, Denzinger S, Manach Q, Compérat E, Boormans J, Jewett M, Stöhr R, Zlotta A, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn B. PD48-05 METRIC SUB-STAGE ACCORDING TO MICRO AND EXTENSIVE LAMINA PROPRIA INVASION IMPROVES PROGNOSTICS IN T1 BLADDER CANCER. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.2353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Richard PO, Martin L, Lavallée L, Violette P, Komisarenko M, Jain K, Jewett M, Finelli A. MP67-20 IDENTIFYING BARRIERS TO THE ADOPTION OF PERCUTANEOUS RENAL TUMOUR BIOPSY IN THE MANAGEMENT OF SMALL RENAL MASSES. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.2056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Fransen van de Putte E, van der Kwast T, Bertz S, Denzinger S, Manach Q, Compérat E, Boormans J, Jewett M, Stöhr R, Zlotta A, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn B. PD57-04 PROGNOSTIC VALUE OF THE WHO 1973 AND 2004 CLASSIFICATION SYSTEMS FOR GRADE IN NON-MUSCLE-INVASIVE T1 BLADDER CANCER. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.2606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA. Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]. Urol Oncol 2017; 35:124. [PMID: 28215848 DOI: 10.1016/j.urolonc.2017.01.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Ross Mason
- Department of Urology, Dalhousie University and QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
| | - Anil Kapoor
- Division of Urology, McMaster University, Hamilton, Ontario, Canada
| | - Zhihui Liu
- Dalai Lama School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Olli Saarela
- Dalai Lama School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Simon Tanguay
- Division of Urology, McGill University, Montreal, Québec, Canada
| | - Michael Jewett
- Department of Surgery(Urology) and Surgical Oncology, University Health Network and Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - Antonio Finelli
- Department of Surgery(Urology) and Surgical Oncology, University Health Network and Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - Louis Lacombe
- Division of Urology, Université Laval, Quebec City, Québec, Canada
| | - Jun Kawakami
- Division of Urology, University of Calgary, Calgary, Alberta, Canada
| | - Ronald Moore
- Division of Urology, University of Alberta, Edmonton, Alberta, Canada
| | | | - Peter Black
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Ricardo A Rendon
- Department of Urology, Dalhousie University and QEII Health Sciences Centre, Halifax, Nova Scotia, Canada.
| |
Collapse
|
31
|
Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W. Quality indicators in the management of bladder cancer: A modified Delphi study. Urol Oncol 2017; 35:328-334. [PMID: 28065393 DOI: 10.1016/j.urolonc.2016.12.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2016] [Revised: 11/12/2016] [Accepted: 12/06/2016] [Indexed: 11/15/2022]
Abstract
BACKGROUND Survival in patients with bladder cancer has only moderately improved over the past 2 decades. A potential reason for this is nonadherence to clinical guidelines and best practice, leading to wide variations in care. Common quality indicators (QIs) are needed to quantify adherence to best practice and provide data for benchmarking and quality improvement. OBJECTIVE To produce an evidence- and consensus-based list of QIs for the management of bladder cancer. METHODS A modified Delphi method was used to develop the indicator list. Candidate indicators were extracted from the literature and rated by a 27-member Canadian expert panel in several rounds until consensus was reached on the final list of indicators. In rounds with numeric ratings, a frequency analysis was performed. RESULTS A total of 86 indicators were rated, 52 extracted from the literature and 34 suggested by the panel. After iterative rounds of ratings and discussion, a final list of 60 QIs spanning several disciplines and phases of the cancer care continuum was developed. CONCLUSIONS This is the first study to comprehensively produce common QIs representing structure, process, and outcome measures in bladder cancer management. Though developed in Canada, these indicators can be used in other countries with slight modifications to track performance and improve care.
Collapse
Affiliation(s)
- Satya R Khare
- Department of Family Medicine, McGill University, Montreal, QC, Canada
| | - Armen Aprikian
- Department of Urology, McGill University Health Centre, Montreal, QC, Canada
| | - Peter Black
- Department of Urology, University of British Columbia, Vancouver, BC, Canada
| | - Normand Blais
- Division of Medical Oncology, University of Montreal, Montreal, QC, Canada
| | - Chris Booth
- Department of Oncology, Queen's University, Kingston, ON, Canada
| | - Fadi Brimo
- Department of Pathology, McGill University Health Centre, Montreal, QC, Canada
| | - Joseph Chin
- Division of Urology, Western University, London, ON, Canada
| | - Peter Chung
- Department of Radiation Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - Libni Eapen
- Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada
| | - Adrian Fairey
- Division of Urology, University of Alberta, Edmonton, AB, Canada
| | - Neil Fleshner
- Departments of Surgery (Urology), Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
| | - Yves Fradet
- Division of Urology, Laval University, Quebec City, QC, Canada
| | - Geoffrey Gotto
- Division of Urology, University of Calgary, Calgary, AB, Canada
| | - Jonathan Izawa
- Division of Urology, Western University, London, ON, Canada
| | - Michael Jewett
- Departments of Surgery (Urology), Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
| | - Girish Kulkarni
- Departments of Surgery (Urology), Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
| | - Louis Lacombe
- Division of Urology, Laval University, Quebec City, QC, Canada
| | - Ron Moore
- Division of Urology, University of Alberta, Edmonton, AB, Canada
| | - Chris Morash
- Division of Urology, University of Ottawa, Ottawa, ON, Canada
| | - Scott North
- Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada
| | - Ricardo Rendon
- Division of Urology, Dalhousie University, Halifax, NS, Canada
| | - Fred Saad
- Division of Urology, University of Montreal, QC, Canada
| | - Bobby Shayegan
- Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Robert Siemens
- Department of Oncology, Queen's University, Kingston, ON, Canada; Department of Urology, Queen's University, Kingston, ON, Canada
| | - Alan So
- Department of Urology, University of British Columbia, Vancouver, BC, Canada
| | - Srikala S Sridhar
- Department of Medical Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | - Samer L Traboulsi
- Department of Urology, McGill University Health Centre, Montreal, QC, Canada
| | - Wassim Kassouf
- Department of Urology, McGill University Health Centre, Montreal, QC, Canada.
| |
Collapse
|
32
|
Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA. The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. Urol Oncol 2016; 34:486.e1-486.e7. [DOI: 10.1016/j.urolonc.2016.05.025] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Revised: 05/02/2016] [Accepted: 05/23/2016] [Indexed: 10/21/2022]
|
33
|
Hosni A, Warde P, Jewett M, Bedard P, Hamilton R, Moore M, Nayan M, Huang R, Atenafu EG, O'Malley M, Sweet J, Chung P. Clinical Characteristics and Outcomes of Late Relapse in Stage I Testicular Seminoma. Clin Oncol (R Coll Radiol) 2016; 28:648-54. [PMID: 27339401 DOI: 10.1016/j.clon.2016.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 05/16/2016] [Accepted: 06/23/2016] [Indexed: 01/31/2023]
Abstract
AIMS To identify the characteristics and outcomes associated with late relapse in stage I seminoma. MATERIALS AND METHODS A retrospective review was carried out of all patients with stage I seminoma managed at our institution between 1981 and 2011. Data were obtained from a prospectively maintained database. Late relapse was defined as tumour recurrence > 2 years after orchiectomy. RESULTS Overall, 1060 stage I seminoma patients were managed with active surveillance (n=766) or adjuvant radiotherapy (n=294). At a median follow-up of 10.6 years (range 1.2-30), 142 patients relapsed at a median (range) of 14 (3-129) months; 128 on active surveillance and 14 after adjuvant radiotherapy. The late relapse rate for the active surveillance and adjuvant radiotherapy groups was 4% and 1%, respectively. There was no specific clinicopathological factor associated with late relapse. Isolated para-aortic node(s) was the most common relapse site in active surveillance patients either in late (88%) or early relapse (82%). Among the active surveillance group, no patients with late relapse subsequently developed a second relapse after either salvage radiotherapy (n=25) or chemotherapy (n=6), whereas in early relapse patients a second relapse was reported in seven (10%) of 72 patients treated with salvage radiotherapy and one (4%) of 23 patients who received chemotherapy; all second relapses were subsequently salvaged with chemotherapy. No patient in the adjuvant radiotherapy group developed a second relapse after salvage chemotherapy (n=10) or inguinal radiotherapy/surgery (n=4). Of seven deaths, only one was related to seminoma. Among active surveillance patients, the 10 year overall survival for late and early relapse groups were 100% and 96% (P = 0.2), whereas the 10 year cancer-specific survival rates were 100% and 99% (P = 0.3), respectively. CONCLUSIONS In stage I seminoma, the extent and pattern of late relapse is similar to that for early relapse. For active surveillance patients, selective use of salvage radiotherapy/chemotherapy for relapse results in excellent outcomes regardless of the timing of relapse, whereas salvage radiotherapy for late relapse seems to be associated with a minimal risk of second relapse.
Collapse
Affiliation(s)
- A Hosni
- Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - P Warde
- Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - M Jewett
- Department of Surgical Oncology (Urology), Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - P Bedard
- Department of Medical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - R Hamilton
- Department of Surgical Oncology (Urology), Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - M Moore
- Department of Medical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - M Nayan
- Department of Surgical Oncology (Urology), Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - R Huang
- Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - E G Atenafu
- Department of Biostatistics, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - M O'Malley
- Department of Medical Imaging, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - J Sweet
- Department of Pathology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada
| | - P Chung
- Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
34
|
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387:2008-16. [PMID: 26969090 PMCID: PMC4878938 DOI: 10.1016/s0140-6736(16)00559-6] [Citation(s) in RCA: 436] [Impact Index Per Article: 54.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND Renal-cell carcinoma is highly vascular, and proliferates primarily through dysregulation of the vascular endothelial growth factor (VEGF) pathway. We tested sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced renal-cell carcinoma, in patients with resected local disease at high risk for recurrence. METHODS In this double-blind, placebo-controlled, randomised, phase 3 trial, we enrolled patients at 226 study centres in the USA and Canada. Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, renal, and hepatic function. Patients were stratified by recurrence risk, histology, Eastern Cooperative Oncology Group (ECOG) performance status, and surgical approach, and computerised double-blind randomisation was done centrally with permuted blocks. Patients were randomly assigned (1:1:1) to receive 54 weeks of sunitinib 50 mg per day orally throughout the first 4 weeks of each 6 week cycle, sorafenib 400 mg twice per day orally throughout each cycle, or placebo. Placebo could be sunitinib placebo given continuously for 4 weeks of every 6 week cycle or sorafenib placebo given twice per day throughout the study. The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to-treat population. All treated patients with at least one follow-up assessment were included in the safety analysis. This trial is registered with ClinicalTrials.gov, number NCT00326898. FINDINGS Between April 24, 2006, and Sept 1, 2010, 1943 patients from the National Clinical Trials Network were randomly assigned to sunitinib (n=647), sorafenib (n=649), or placebo (n=647). Following high rates of toxicity-related discontinuation after 1323 patients had enrolled (treatment discontinued by 193 [44%] of 438 patients on sunitinib, 199 [45%] of 441 patients on sorafenib), the starting dose of each drug was reduced and then individually titrated up to the original full doses. On Oct 16, 2014, because of low conditional power for the primary endpoint, the ECOG-ACRIN Data Safety Monitoring Committee recommended that blinded follow-up cease and the results be released. The primary analysis showed no significant differences in disease-free survival. Median disease-free survival was 5·8 years (IQR 1·6-8·2) for sunitinib (hazard ratio [HR] 1·02, 97·5% CI 0·85-1·23, p=0·8038), 6·1 years (IQR 1·7-not estimable [NE]) for sorafenib (HR 0·97, 97·5% CI 0·80-1·17, p=0·7184), and 6·6 years (IQR 1·5-NE) for placebo. The most common grade 3 or worse adverse events were hypertension (105 [17%] patients on sunitinib and 102 [16%] patients on sorafenib), hand-foot syndrome (94 [15%] patients on sunitinib and 208 [33%] patients on sorafenib), rash (15 [2%] patients on sunitinib and 95 [15%] patients on sorafenib), and fatigue 110 [18%] patients on sunitinib [corrected]. There were five deaths related to treatment or occurring within 30 days of the end of treatment; one patient receiving sorafenib died from infectious colitis while on treatment and four patients receiving sunitinib died, with one death due to each of neurological sequelae, sequelae of gastric perforation, pulmonary embolus, and disease progression. Revised dosing still resulted in high toxicity. INTERPRETATION Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treatment discontinuation occurred because of excessive toxicity, despite dose reductions. These results provide a strong rationale against the use of these drugs for high-risk kidney cancer in the adjuvant setting and suggest that the biology of cancer recurrence might be independent of angiogenesis. FUNDING US National Cancer Institute and ECOG-ACRIN Cancer Research Group, Pfizer, and Bayer.
Collapse
Affiliation(s)
- Naomi B Haas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
| | | | | | | | | | - Christopher Kane
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Michael Jewett
- Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
| | | | | | - Michael Pins
- University of Illinois College of Medicine, Chicago, IL, USA
| | - George Wilding
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David Cella
- Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Lynne Wagner
- Wake Forest School of Medicine, Winston Salem, NC, USA
| | - Surena Matin
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Timothy M Kuzel
- Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | | | | | - Igor Puzanov
- Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | | | | | - Michael Carducci
- Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
| | | | | |
Collapse
|
35
|
Paterson C, Chin YF, Sweeney C, Jewett M, Nabi G. PD46-08 FACTORS THAT PREDICT GROWTH KINETICS IN SOLID SMALL RENAL MASSES (<4CM) ON ACTIVE SURVEILLANCE. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Psutka S, Jewett M, Fadaak K, Finelli A, Thompson RH, Herrin J, Lohse C, Boorjian S, Stewart-Merrill S, Atwell T, Schmit G, Costello B, Legere L, Shah N, Leibovich B. MP73-11 A COMPREHENSIVE COMPETING RISK CALCULATOR FOR PATIENTS WITH CORTICAL RENAL MASSES < 10CM: A NOVEL CLINICAL DECISION AID FOR SHARED DECISION-MAKING REGARDING INDIVIDUALIZED TREATMENT SELECTION. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
ALKASAB THAMIR, Ahmad A, Rechard P, Mohamed A, Garisto J, Fadaak K, Finelli A, Hamilton R, Kulkarni G, Jewett M, Zlotta A, Fleshner N. MP53-12 THE ROLE OF PROSTATE CANCER ANTIGEN 3 (PCA3) TEST AND MULTI-PARAMETRIC PROSTATIC MAGNETIC RESONANCE IMAGING (MPMRI) AMONG PATIENTS WITH PRIOR NEGATIVE BIOPSY: CORRELATION WITH RADICAL PROSTATECTOMY PATHOLOGY. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.509] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Kulkarni G, Hermanns T, Li K, Wei Y, Bhindi B, Kuk C, Sridhar S, van der Kwast T, Chung P, Bristow R, Warde P, Michael M, Fleshner N, Jewett M, Zlotta A. PD39-08 PROPENSITY-MATCHED COMPARISON OF SURVIVAL OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY VERSUS BLADDER PRESERVING TRIMODAL THERAPY. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Matta R, Al Matar A, Bhindi B, Zlotta A, Fleshner N, Jewett M, Hamilton R, Finelli A, Kulkarni G. MP13-02 IS RE-RESECTION NECESSARY? RE-RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER AT A TERTIARY CARE CENTER. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Mason R, Kapoor A, Liu Z, Saarela O, Tanguay SI, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon R. MP75-09 THE NATURAL HISTORY OF RENAL FUNCTION AFTER SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Sayyid R, Gleave M, Hersey K, Maloni R, Hurtado-Coll A, Evans A, Kulkarni G, Finelli A, Zlotta A, Hamilton R, Jewett M, Fleshner N. PD37-04 A PHASE II, RANDOMIZED, OPEN LABEL STUDY OF NEOADJUVANT DEGARELIX VERSUS LHRH AGONIST IN PROSTATE CANCER PATIENTS PRIOR TO RADICAL PROSTATECTOMY. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J 2016; 10:E46-80. [PMID: 26977213 DOI: 10.5489/cuaj.3583] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This initiative was undertaken in response to concerns regarding the variation in management and in outcomes of patients with bladder cancer throughout centres and geographical areas in Canada. Population-based data have also revealed that real-life survival is lower than expected based on data from clinical trials and/or academic centres. To address these perceived shortcomings and attempt to streamline and unify treatment approaches to bladder cancer in Canada, a multidisciplinary panel of expert clinicians was convened last fall for a two-day working group consensus meeting. The panelists included urologic oncologists, medical oncologists, radiation oncologists, patient representatives, a genitourinary pathologist, and an enterostomal therapy nurse. The following recommendations and summaries of supporting evidence represent the results of the presentations, debates, and discussions. Methodology
Collapse
Affiliation(s)
- Wassim Kassouf
- Department of urology, McGill University Health Centre, Montreal, QC, Canada
| | - Armen Aprikian
- Department of urology, McGill University Health Centre, Montreal, QC, Canada
| | - Peter Black
- Department of urology, University of British Columbia, Vancouver, BC, Canada
| | - Girish Kulkarni
- Department of surgery (urology) and surgical oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | - Jonathan Izawa
- Division of urology, Western University, London, ON, Canada
| | - Libni Eapen
- Division of radiation oncology, University of Ottawa, Ottawa, ON, Canada
| | - Adrian Fairey
- Division of urology, University of Alberta, Edmonton, AB, Canada
| | - Alan So
- Department of urology, University of British Columbia, Vancouver, BC, Canada
| | - Scott North
- Medical oncology, University of Alberta, Edmonton, AB, Canada
| | - Ricardo Rendon
- Division of urology, Dalhousie University, Halifax, NS, Canada
| | - Srikala S Sridhar
- Medical oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | - Tarik Alam
- School of nursing, Dawson College, Montreal, QC, Canada
| | - Fadi Brimo
- Pathology, McGill University Health Centre, Montreal, QC, Canada
| | - Normand Blais
- Division of medical oncology, University of Montreal, Montreal, QC, Canada
| | - Chris Booth
- Departments of oncology, Queen's University, Kingston, ON, Canada
| | - Joseph Chin
- Division of urology, Western University, London, ON, Canada
| | - Peter Chung
- Radiation oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - Yves Fradet
- Division of urology, Laval University, Quebec City, QC, Canada
| | - Michael Jewett
- Department of surgery (urology) and surgical oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | - Ron Moore
- Division of urology, University of Alberta, Edmonton, AB, Canada
| | - Chris Morash
- Urology, University of Ottawa, Ottawa, ON, Canada
| | - Bobby Shayegan
- Division of urology, McMaster University, Hamilton, ON, Canada
| | - Geoffrey Gotto
- Division of urology, University of Calgary, Calgary, AB, Canada
| | - Neil Fleshner
- Department of surgery (urology) and surgical oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada
| | - Fred Saad
- Urology, University of Montreal, Montreal, QC, Canada
| | - D Robert Siemens
- Departments of oncology, Queen's University, Kingston, ON, Canada;; Urology, Queen's University, Kingston, ON, Canada
| |
Collapse
|
43
|
Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, Krylov S, Yousef GM. Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell-Cell Communication in Renal Cell Carcinoma. Eur Urol Focus 2015; 2:210-218. [PMID: 28723537 DOI: 10.1016/j.euf.2015.11.006] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Accepted: 11/06/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND Apart from an invasive biopsy, currently no tools are available to confirm the diagnosis of clear cell renal cell carcinoma (ccRCC); this resulted in approximately 30% of patients being diagnosed with metastatic disease. OBJECTIVE To determine whether urinary microRNAs (miRNAs) can serve as biomarkers to confirm the diagnosis of ccRCC. DESIGN, SETTING, AND PARTICIPANTS Global miRNA expression was assessed in 28 preoperative urine samples from patients with ccRCC and 18 healthy participants. The independent validation set consisted of 81 ccRCC patients, 24 patients with benign lesions, and 33 healthy participants. We extracted both cell-free and exosomal RNA for miRNA expression analysis using miRNA-specific polymerase chain reaction assays. We also investigated exosomal miRNA secretion in cell line models and performed exosome transfer between RCC and endothelial cell types. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Receiver operating characteristic analysis was applied to identify the discrimination power of miRNAs. RESULTS AND LIMITATIONS Overall, miR-126-3p combined with miR-449a or with miR-34b-5p could significantly distinguish ccRCC patients from healthy participants (miR-126-3p-miR-449a: area under the curve [AUC]: 0.84; 95% confidence interval [CI], 0.7620-0.9151; p<0.001; miR-126-3p-miR-34b-5p: AUC: 0.79; 95% CI, 0.7013-0.8815; p<0.001). The combination of miR-126-3p and miR-34b-5p was also able to distinguish small renal masses (pT1a, ≤4cm) from healthy controls (AUC: 0.79; 95% CI, 0.6848-0.8980; p<0.001). Using miR-126-3p and miR-486-5p in combination, we were able to differentiate between benign lesions and ccRCC (AUC: 0.85; 95% CI, 0.7295-0.9615; p<0.01). The expression of a number of miRNAs returned to a level comparable with health after surgery. Kidney cancer cell lines were found to secrete exosomal miR-126-3p, miR-17-5p, miR-21-3p, and miR-25-3p, and these miRNAs were found to be internalized by other cell types. CONCLUSIONS We identified exosomal miRNAs as potential noninvasive diagnostic urinary biomarkers for ccRCC and provided evidence that miRNAs are secreted by the tumor and can function as a tool for intercellular communication. PATIENT SUMMARY We identified urinary microRNAs that can serve as diagnostic biomarkers for clear cell renal cell carcinoma.
Collapse
Affiliation(s)
- Henriett Butz
- Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Roy Nofech-Mozes
- Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada
| | - Qiang Ding
- Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada
| | - Heba W Z Khella
- Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada
| | - Peter M Szabó
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Michael Jewett
- Department of Surgery, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Antonio Finelli
- Department of Surgery, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Jason Lee
- Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Michael Ordon
- Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Robert Stewart
- Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Sergey Krylov
- Department of Chemistry and Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario, Canada
| | - George M Yousef
- Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
44
|
Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. [Not Available]. Prog Urol 2015; 24:806-7. [PMID: 26461579 DOI: 10.1016/j.purol.2014.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Y Neuzillet
- Service d'urologie, hôpital Foch, université de Versailles-Saint-Quentin-en-Yvelines, Suresnes, France.
| | - L Mertens
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - S Shariat
- Urology and Pathology, University of Texas, Southwestern Medical center, Dallas, États-unis
| | - P Bostrom
- Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - T Mirtti
- Urology and Pathology, University of Turku, Turku, Finlande
| | - A Sagalowsky
- Urology and Pathology, University of Texas, Southwestern Medical center, Dallas, États-unis
| | - R Ashfaq
- Urology and Pathology, University of Texas, Southwestern Medical center, Dallas, États-unis
| | - A Broeks
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - M Van der Heijden
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - D Peters
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - C Curial
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - J De Jong
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - S Horenblas
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - C Hurst
- Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, Royaume-Uni
| | - D Tomlinson
- Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, Royaume-Uni
| | - M Knowles
- Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, Royaume-Uni
| | - B Bapat
- Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - M Jewett
- Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - A Zlotta
- Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - J Sanders
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| | - Y Lotan
- Urology and Pathology, University of Texas, Southwestern Medical center, Dallas, États-unis
| | - T Van der Kwast
- Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - B Van Rhijn
- Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas
| |
Collapse
|
45
|
Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 2015; 21:4048-54. [PMID: 25967143 PMCID: PMC4573791 DOI: 10.1158/1078-0432.ccr-15-0215] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Accepted: 04/13/2015] [Indexed: 12/17/2022]
Abstract
PURPOSE Sunitinib and sorafenib are used widely in the treatment of renal cell carcinoma (RCC). These agents are associated with a significant incidence of cardiovascular (CV) dysfunction and left ventricular ejection fraction (LVEF) declines, observed largely in the metastatic setting. However, in the adjuvant population, the CV effects of these agents remain unknown. We prospectively defined the incidence of cardiotoxicity among resected, high-risk RCC patients treated with these agents. EXPERIMENTAL DESIGN Sunitinib, sorafenib, or placebo was administered for up to 12 months in patients with high-risk, resected RCC. LVEF was measured by multigated acquisition (MUGA) scans at standard intervals. Additional CV adverse events were reported according to NCI Common Terminology Criteria for Adverse Events (CTCAE). RESULTS Among 1,943 patients randomized, 1,599 had at least 1 post-baseline MUGA. Within 6 months, 21 patients (1.3%) experienced a cardiac event, defined as an LVEF decline from baseline that was >15% and below the institutional lower limit of normal. Nine of 513 patients (1.8%) were on sunitinib, 7 of 508 (1.4%) on sorafenib, and 5 of 578 (0.9%) on placebo (P = 0.28 and 0.56 comparing sunitinib and sorafenib to placebo, respectively). With dose interruption or adjustment, 16 of the 21 recovered their LVEF to >50%. The incidence of symptomatic heart failure, arrhythmia, or myocardial ischemia did not differ among groups. CONCLUSIONS In the adjuvant setting, we prospectively define low incidence of cardiotoxicity with sunitinib and sorafenib. These findings may be related to close CV monitoring, or potentially to fewer CV comorbidities in our nonmetastatic population.
Collapse
Affiliation(s)
- Naomi B Haas
- University of Pennsylvania, Philadelphia, Pennsylvania.
| | | | - Bonnie Ky
- University of Pennsylvania, Philadelphia, Pennsylvania
| | | | | | | | | | - Lori Wood
- Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | - Janice J Dutcher
- Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York
| | - George Wilding
- Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin
| | - Robert S DiPaola
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| |
Collapse
|
46
|
Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. Mol Oncol 2015; 9:1667-77. [PMID: 26051997 DOI: 10.1016/j.molonc.2015.04.007] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 04/18/2015] [Accepted: 04/20/2015] [Indexed: 02/03/2023] Open
Abstract
Papillary renal cell carcinoma (pRCC) is the second most common RCC subtype and can be further classified as type 1 (pRCC1) or 2 (pRCC2). There is currently minimal understanding of pRCC1 pathogenesis, and treatment decisions are mostly empirical. The aim of this study was to identify biological pathways that are involved in pRCC1 pathogenesis using an integrated genomic approach. By microarray analysis, we identified a number of significantly dysregulated genes and microRNAs (miRNAs) that were unique to pRCC1. Integrated bioinformatics analyses showed enrichment of the focal adhesion and extracellular matrix (ECM) pathways. We experimentally validated that many members of these pathways are dysregulated in pRCC1. We identified and experimentally validated the downregulation of miR-199a-3p in pRCC1. Using cell line models, we showed that miR-199a-3p plays an important role in pRCC1 pathogenesis. Gain of function experiments showed that miR-199a-3p overexpression significantly decreased cell proliferation (p = 0.013). We also provide evidence that miR-199a-3p regulates the expression of genes linked to the focal adhesion and ECM pathways, such as caveolin 2 (CAV2), integrin beta 8 (ITGB8), MET proto-oncogene and mammalian target of rapamycin (MTOR). Using a luciferase reporter assay, we further provide evidence that miR-199a-3p overexpression decreases the expression of MET and MTOR. Using an integrated gene/miRNA approach, we provide evidence linking miRNAs to the focal adhesion and ECM pathways in pRCC1 pathogenesis. This novel information can contribute to the development of effective targeted therapies for pRCC1, for which there is none currently available in the clinic.
Collapse
Affiliation(s)
- Samantha Jane Wala
- The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
| | - Jason Raj Karamchandani
- Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
| | - Rola Saleeb
- Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
| | - Andrew Evans
- Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada; Department of Pathology, Toronto General Hospital, Toronto, Ontario, Canada.
| | - Qiang Ding
- The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
| | - Rania Ibrahim
- The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
| | - Michael Jewett
- Department of Surgery, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
| | - Maria Pasic
- Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada; Department of Laboratory Medicine, St. Joseph's Health Centre, 30 Queensway, Ontario M6R 1B5, Canada.
| | - Antonio Finelli
- Department of Surgery, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
| | - Kenneth Pace
- Department of Surgery, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
| | - Evi Lianidou
- Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.
| | - George Makram Yousef
- The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
| |
Collapse
|
47
|
Atri M, Tabatabaeifar L, Jang HJ, Finelli A, Moshonov H, Jewett M. Accuracy of Contrast-enhanced US for Differentiating Benign from Malignant Solid Small Renal Masses. Radiology 2015; 276:900-8. [PMID: 25919803 DOI: 10.1148/radiol.2015140907] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
PURPOSE To test the hypothesis that qualitative and quantitative features of contrast material-enhanced ultrasonography (US) can be used to differentiate benign from malignant small renal masses. MATERIALS AND METHODS This is an institutional review board approved, HIPAA-compliant prospective study with written informed consent. Patients with histologically characterized solid small renal masses, excluding lipid-rich angiomyolipomas, underwent qualitative contrast-enhanced US with a combination of three different US machines. A subgroup of patients underwent quantitative contrast-enhanced US. Patients received a bolus injection of 0.2 mL of contrast material for qualitative and quantitative evaluations and were followed for 3 minutes. Two radiologists independently reviewed videotaped qualitative contrast-enhanced US examinations and were blinded to the final diagnoses. Features that were evaluated included lesion vascularity relative to the adjacent cortex in the arterial phase, the presence of a capsule, homogeneity, the pattern of vascularity, and washout. One radiologist separately reviewed a subset of contrast-enhanced US examinations that were performed with all three machines. Parameters of a first-pass time intensity curve were calculated for quantitative analysis. The Mann-Whitney test was used for quantitative parameters, the χ(2) or Fisher exact test was used for qualitative parameters, and κ statistics and Fleiss methodology were used to determine interobserver and intermachine agreement. RESULTS The study population consisted of 91 patients (35 women and 56 men) with 94 lesions. The mean age was 62 years ± 14 (range, 21-91). Three patients had two lesions each, which were evaluated at two different sessions. There were 26 benign small renal masses (including 18 oncocytomas, seven lipid-poor angiomyolipomas, and one hemangioblastoma) and 68 malignant masses (including 41 clear cell, 20 papillary, and seven chromophobe renal cell carcinomas [RCCs[) that were 1.1-4.0 cm in diameter (mean, 2.7 cm ± 0.9). All patients underwent contrast-enhanced US on the same one machine, and 68 patients were imaged on all three machines. Vascularity was present in all lesions (n = 94) at contrast-enhanced US. Lesion hypovascularity relative to the adjacent cortex in the arterial phase was seen in only malignant lesions by both reviewers; reviewer 1 saw hypovascularity in 24 of 94 lesions (P = .0001), and reviewer 2 saw hypovascularity in 21 of 94 lesions (P = .0006), for a specificity of 100% (95% confidence interval [CI]: 84, 100). This feature had κ values of 0.91 (95%CI: 0.82, 1.00) between the two reviewers and 0.85 (95% CI: 0.72, 0.99) between the three machines. Eighteen of 20 papillary RCCs were hypovascular. Quantitative parameters of area under the receiver operating characteristics curve, peak intensity, wash-in slope of 10%-90% and 5%-45%, and washout slope of 100%-10% and 50%-10% were significantly higher in malignant renal masses (P = .018, P = .002, P = .036, P = .016, P = .001, and P = .005, respectively) than in benign lesions. CONCLUSION Excluding lipid-rich angiomyolipoma, hypovascularity-which has high interobserver and intermachine agreement-of solid small renal masses relative to the cortex in the arterial phase has 100% specificity (95% CI: 84, 100) for detecting malignancy, most often papillary RCC.
Collapse
Affiliation(s)
- Mostafa Atri
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| | - Leila Tabatabaeifar
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| | - Hyun-Jung Jang
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| | - Anthony Finelli
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| | - Hadas Moshonov
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| | - Michael Jewett
- From the Departments of Medical Imaging (M.A., L.T., H.J.J.), Urology (A.F., M.J.), and Statistics (H.M.), University Health Network, Toronto General Hospital, 585 University Ave, Toronto, ON, Canada M5G 2N2
| |
Collapse
|
48
|
Uzzo R, Manola J, Kane C, Wood C, Jewett M, DiPaola R, Haas N. PD35-04 EFFECTS OF PERIOPERATIVE VARIABLES ON TIMING OF ADJUVANT RCC THERAPY: RESULTS FROM THE ASSURE TRIAL (ECOG 2805). J Urol 2015. [DOI: 10.1016/j.juro.2015.02.2227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Alkasab T, Kulkarni G, Hamilton R, Zlotta A, Finelli A, Jewett M, Fleshner N. MP86-16 FATE OF PROSTATE CANCER ANTIGEN 3 (PCA3) LEVELS MORE THAN 100: DOES INFLAMMATION PLAY A ROLE?? J Urol 2015. [DOI: 10.1016/j.juro.2015.02.1925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Joshua AM, Zannella V, Bowes B, Koritzinsky M, Sweet J, Evans A, Trachtenberg J, Jewett M, Finelli A, Fleshner N, Pollak M. Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma. Clin Trials 2014. [DOI: 10.1158/1538-7445.am2012-ct-04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|